Thermo Fisher Scientific has signed an agreement with Cynvenio Biosystems to distribute Cynvenio's LiquidBiopsy platform. The combination of Cynvenio's rare cell enrichment technology with Thermo Fisher's Ion Torrent PGM sequencing workflow provides the first commercially available solution to analyze circulating tumor cells and cell-free DNA from a single blood draw within 48 hours. This end-to-end liquid biopsy solution allows researchers to conduct multiplexed genomic analysis of serial blood samples for applications such as cancer monitoring and therapy response.

1.
FOR
IMMEDIATE
RELEASE
Media
Contact
Information:
Mauricio
Minotta
Carlsbad,
CA,
USA
760-­‐929-­‐2456
Mauricio.minotta@thermofisher.com
Thermo
Fisher
Scientific
Signs
Distribution
Agreement
with
Cynvenio
for
LiquidBiopsy
Platform
Combination
of
Ion
Torrent
PGM
workflow
and
rare
cell
enrichment
technology
provides
the
industry’s
only
commercially
available
sample-­‐to-­‐genomic
data
solution
for
analyzing
circulating
tumor
cells
and
cell-­‐free
DNA
from
a
single
blood
draw
CARLSBAD,
Calif.,
Jan.
13,
2015
–
Thermo
Fisher
Scientific
today
announced
it
has
signed
an
agreement
with
Cynvenio
Biosystems
Inc.,
a
molecular
testing
company
focused
on
the
genomic
analysis
of
tumor
biomarkers
in
the
bloodstream,
for
rights
to
distribute
its
LiquidBiopsy
platform.
The
addition
of
Cynvenio’s
rare
cell
enrichment
technology
complements
Thermo
Fisher’s
Ion
Torrent
Personal
Genome
Machine
(PGM)
workflow
and
positions
the
company
as
the
only
one
in
the
industry
to
offer
a
comprehensive
sample-­‐to-­‐genomic
data
solution
for
research
using
a
single
blood
draw
for
analysis
of
circulating
tumor
cells
(CTC),
cell-­‐free
DNA
(cfDNA)
and
normal
DNA
in
less
than
48
hours.
The
workflow
enables
researchers
to
conduct
highly
multiplexed
analyses
on
serially
collected
blood
samples.
The
molecular
analysis
of
CTCs
and
cfDNA
that
are
released
into
the
bloodstream
offers
a
promising
new
research
tool
to
aid
in
the
development
of
future
solutions
for
early
cancer
detection
and
therapy
selection
without
the
need
for
a
tumor
tissue
biopsy.
Studies
have
shown
that
serial
monitoring
of
molecularly
profiled
CTCs
and
cfDNA
both
during
and
after
therapy
holds
great
potential
to
better
understand
the
mechanisms
of
therapy
response
and
tumor
recurrence.
Alternative
methods
include
tissue
biopsies,
which
are
costly,
highly
invasive
and
vary
in
the
amount
of
sample
that
can
be
retrieved.
“As
a
company,
we
are
dedicated
to
facilitating
a
new
era
of
individualized
medicine,”
said
Cynvenio
Chief
Executive
Officer
André
de
Fusco.
“To
that
end,
we
see
incredible
value
that
our
platform
and
Thermo
Fisher’s
next
generations
sequencing
workflow
can
bring
to
translational
researchers
globally.”
The
automated
LiquidBiopsy
platform
is
designed
to
efficiently
extract
and
isolate
CTCs
from
a
standard
blood
draw
in
preparation
for
both
high
content
imaging
and
genomic
analysis.
The
high
CTC
purity
rate,
in
conjunction
with
the
Ion
Torrent
PGM’s
capability
to
accurately
sequence
as
little
as
10ng
of
DNA,
enables
highly
multiplexed
interrogation
on
one
Ion
318
sequencing
chip
from
a
single
blood
sample.
The
workflow
also
incorporates
the
Ion
Torrent
Chef
System
for
automated
sample
prep
and
the
Ion

2. Torrent
AmpliSeq
Cancer
Hot
Spot
Panel
v2,
which
targets
about
2,800
specific
gene
mutations
for
sequencing
prior
to
final
analysis
with
the
Ion
Torrent
Reporter
software.
“In
our
evaluation
of
peripheral
monitoring
technologies
on
the
market,
Cynvenio’s
LiquidBiopsy
platform
offers
the
most
compatible
addition
to
our
next
generation
sequencing
workflow,
particularly
as
it
applies
to
our
evolving
oncology
strategy,”
said
Chris
Linthwaite,
president,
Genetic,
Medical
and
Applied
Sciences,
Thermo
Fisher
Scientific.
“The
agreement
with
Cynvenio
also
underscores
our
commitment
to
provide
our
oncology
research
customers
with
innovative
tools
to
help
advance
the
future
of
cancer
care.”
Cynvenio’s
liquid
biopsy
platform
as
well
as
the
Ion
Torrent
PGM,
Ion
Torrent
Chef
and
AmpliSeq
Cancer
Hot
Spot
Panel
v2
are
For
Research
Use
only.
Not
for
use
in
diagnostic
procedures.
About
Thermo
Fisher
Scientific
Thermo
Fisher
Scientific
Inc.
is
the
world
leader
in
serving
science,
with
revenues
of
$17
billion
and
50,000
employees
in
50
countries.
Our
mission
is
to
enable
our
customers
to
make
the
world
healthier,
cleaner
and
safer.
We
help
our
customers
accelerate
life
sciences
research,
solve
complex
analytical
challenges,
improve
patient
diagnostics
and
increase
laboratory
productivity.
Through
our
four
premier
brands
–
Thermo
Scientific,
Life
Technologies,
Fisher
Scientific
and
Unity
Lab
Services
–
we
offer
an
unmatched
combination
of
innovative
technologies,
purchasing
convenience
and
comprehensive
support.
For
more
information,
please
visit
www.thermofisher.com.
#
#
#